• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 141

Featured

Featured posts
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

PT347 – Christopher Koddermann – Rescheduling Psilocybin, Patents and IP, and The Entourage Effect

Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update

FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Small Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction Study

What Drug Is Best for Sex?

Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including...

Psychedelic Bulletin: DMT for Stroke; MindMed’s Drug Discovery Partnership; Psychedelics are...

Psychedelic Business News Spotlight: February 12, 2021

The Structure-Activity Relationship of Psilocybin Analogs

New Jersey Gov Signs Bill Reclassifying Psilocybin

PTSF 46 – Patents, Prohibition, Health, and Happiness

New Age Animism: A Consciousness Theory With a Psychedelic Twist

Progressive Doctor Thinks Psychedelics May Be Used to Revive Comatose Patients

MINDCURE Announces Listing of Warrants

1...140141142...150Page 141 of 150

EDITOR PICKS

PT347 – Christopher Koddermann – Rescheduling Psilocybin, Patents and IP, and...

Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

atai Life Sciences Reports Second Quarter 2022 Financial Results & Business...

POPULAR POSTS

Having Sex on DMT: What You Need to Know

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book...

How to Get DMT: Obtaining the Spirit Molecule

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©